Результаты поиска

Single-cell technologies in deciphering drug resistance of multiple myeloma: mechanistic insights and clinical translation prospects.

The greatest hindrance to long-lasting remission in multiple myeloma (MM) is drug resistance and is modulated by the complex interaction of tumor-intrinsic plasticity and microenvironmental co-evolution. Multi-omics of single cells has transformed the exploration of this complexity, and has solved the dynamics of clonal architecture and ecosystem at an unprecedented resolution. The present review summarizes critical relapse-driver revealed by single cell technologies, including existing resistant subclones and non-genetic programs, as well as inflammatory stromal remodeling and immune exhausti…

Corticosteroid-Resistant Secondary Immune Thrombocytopenia in Smoldering Multiple Myeloma Successfully Treated With Eltrombopag: A Case Report.

Immune thrombocytopenia (ITP) is an uncommon yet clinically significant cause of thrombocytopenia in multiple myeloma (MM). We report a case of an 80-year-old female with severe thrombocytopenia identified during routine follow-up after breast cancer surgery, leading to the simultaneous diagnosis of Smoldering multiple myeloma (sMM) and secondary ITP. Laboratory findings, including an elevated immature platelet fraction, increased platelet-associated immunoglobulin G (IgG), and preserved megakaryopoiesis, supported a diagnosis of immune-mediated platelet destruction. The patient demonstrated o…

Bone marrow hemodilution assessment in multiple myeloma MRD by next generation flow cytometry - a mini review.

Bone marrow hemodilution could compromise next generation flow cytometry based measurable residual disease evaluation in multiple myeloma and may cause false negative results. This review summarizes definitions, markers, indices, mitigation strategies, and current challenges in standardization.

Infection incidence, timing, and predictors in newly diagnosed multiple myeloma: a real-world retrospective cohort study.

BACKGROUND: Infections are a leading cause of morbidity and mortality in multiple myeloma (MM), particularly during the induction phase. Identifying real-world infection patterns and predictors is crucial for guiding preventive strategies. METHODS: This retrospective cohort study included 161 newly diagnosed MM patients who received standard induction therapy at a single tertiary center between 2016 and 2024. Clinical, laboratory, and infection-related parameters were analyzed, with infection during the first 6 months defined as the primary outcome and 12-months analyses as secondary outcomes…

Autologous stem cell transplantation for newly diagnosed multiple myeloma - real-world data from 2,149 Czech patients.

Not available.

Venous thromboembolism prophylaxis in multiple myeloma patients receiving immunomodulatory therapy: a systematic review and meta-analysis.

Patients with multiple myeloma receiving immunomodulatory drugs have an increased risk of venous thromboembolism (VTE), but the comparative effectiveness and safety of available prophylactic strategies remain uncertain. A systematic review and meta-analysis of randomized and prospective studies was conducted in accordance with PRISMA 2020. Studies evaluating aspirin, low-molecular-weight heparin (LMWH), warfarin, direct oral anticoagulants (DOACs), or no prophylaxis in patients receiving immunomodulatory therapy were included. Primary outcomes were symptomatic VTE and major bleeding. Twelve st…

Correction: Single-cell profiling uncovers extracellular vesicle-associated malignant plasma cell subpopulations driving multiple myeloma progression.

[This corrects the article DOI: 10.3389/fimmu.2026.1848792.].

Легочная артериальная сенсорная терапия для сердечно-сосудистого амилоидоза у молодого пациента с множественной миеломой.

ОКРУЖАЮЩАЯ СРЕДА: Оценка объема в сердечной амилоидной цепи освещения (AL) амилоидоз сопряжена с трудностями в ходе высокодозированной химиотерапии и аутологической трансплантации стволовых клеток, поскольку клинические результаты и вес тела могут не точно отражать внутриваскулярную загруженность. Резюме дела: A 45-year-old У человека с множественной миеломой, нефротическим синдромом и сердечным амилоидозом во время индуктивной терапии появились заметные колебания объема. Перед SCT был установлен имплантируемый датчик давления легочной артерии (PAP) для направления диуретиков. 22 мм Hg. В пери…

Spatial profiling identifies a distinct and topographically-defined tumor microenvironment that emerges during multiple myeloma evolution.

The pathobiology of multiple myeloma is influenced by cells of the bone marrow, but whether tumor support is organized in a spatially-defined tumor microenvironment (TME) remains unclear. Using spatial transcriptomics and imaging mass cytometry, we show that myeloma cells initially exist as scattered cells throughout the marrow, yet with disease evolution condense into a spatially-defined TME. Dense tumor nodules contain a cellular ecosystem distinct from the surrounding marrow, enriched for macrophages, conventional dendritic cells, and CD8⁺ T cells, as well as endothelial cells and THY1⁺ mes…

Социально-экономические различия в обеспечении выживания многих миелом в Новом Южном Уэльсе Австралия: исследование на тему " Демографический коорт " .

Введение one :: самые высокие показатели заболеваемости миеломой (ММ) в мире, и это бремя, по прогнозам, значительно возрастет в предстоящие десятилетия. Со временем положение в области выживания улучшилось, однако не ясно, в какой степени оно различается по социально-экономическим группам. Здесь мы использовали демографические данные для оценки различий в уровне выживания по социально-экономическим группам и другим прогнозным факторам лиц с MM в Австралии. 2008 и 2019, как указано в регистре рака Нового Южного Уэльса, с последующими мерами по выживанию 2020. Выявленные лица, имеющие первичный

Совпадение в аннотации оригинала
IntroductionAustralia has one of the highest incidence rates of multiple myeloma (MM) globally, and this burden is projected to increase significantly in the coming decades. Survival has improved over time, but it is not clear how this differs by socioeconomic group. Here, we used population-based data to evaluate survival differences by socioeconomic group …

[Clinical outcomes of idecabtagene vicleucel therapy for relapsed/refractory multiple myeloma: a single-center retrospective analysis].

Idecabtagene vicleucel (ide-cel) is effective for relapsed/refractory multiple myeloma (RRMM), but real-world data in Japan are limited. We retrospectively analyzed 11 patients with RRMM who received ide-cel at our institution. The median age at infusion was 67 years (range, 54-71), and the median number of prior lines of therapy was 4 (range, 3-6). At best response, the overall response rate was 90.0%, with a complete response rate of 60.0%. With a median follow-up of 530 days (range, 198-1,032) among survivors, the 1-year overall survival and progression-free survival rates were 90.9% and 71…

mHealth-Supported Exercise Rehabilitation to Reverse Frailty After Autologous Transplantation in Multiple Myeloma: Randomized Controlled Trial.

BACKGROUND: Frailty is highly prevalent in survivors of multiple myeloma (MM) after autologous hematopoietic cell transplantation and is associated with poor functional recovery and adverse clinical outcomes. Although exercise is known to improve physical function, traditional center-based rehabilitation models are often inaccessible to this population during early posttransplant recovery. Mobile health (mHealth)-supported exercise may offer a scalable alternative; however, evidence in hematologic malignancies remains limited. OBJECTIVE: This study aimed to evaluate the effects of a 16-week m…

High CD163+CD206+ macrophage infiltration in the bone marrow microenvironment of newly diagnosed multiple myeloma patients.

Multiple myeloma (MM) is a neoplastic disease caused by abnormal clonal plasma cells in the bone marrow (BM). Macrophages (MФs) are essential components of BM microenvironment and crucial mediators of plasma cells. Therefore, investigating alterations in the specific MФ subsets within the MM BM microenvironment is of significant importance for elucidating the underlying mechanisms of MM. Here, using flow cytometry, we characterized the dynamics of BM MФ subsets in newly diagnosed multiple myeloma (NDMM) patients and complete remission multiple myeloma (CRMM) patients. We found that NDMM patien…

Orbital Fat Involvement by Metastatic Multiple Myeloma Mimicking Involutional Lower Eyelid Fat Herniation: A Case Report.

PURPOSE: To report an unusual presentation of orbital extramedullary plasmacytoma in a patient with multiple myeloma, clinically mimicking involutional lower eyelid fat herniation. OBSERVATIONS: A 57-year-old man with a history of multiple myeloma in remission presented with a three-month history of progressive fullness of the right lower eyelid. Clinical examination suggested minimal right-sided hyperglobus and asymmetric lower eyelid fat herniation without signs of inflammation. Orbital computerized tomography revealed a hyperdense anterior inferior orbital mass distinct from surrounding fa…

PCIF1-mediated m6Am modification activates USP5/BRD4 axis to promote glycolysis-driven immunosuppression in multiple myeloma.

BACKGROUND: Multiple myeloma (MM) is a malignant plasma cell disorder, with aberrant glycolysis being a key feature driving tumor progression and immune escape. PCIF1, an RNA modification-related protein, has been implicated in tumorigenesis, but its role in regulating MM progression remains unclear. METHODS: Molecular expression was analyzed in bone marrow plasma cells (PCs), MM cell lines, using qRT-PCR and Western blot. Cell viability, apoptosis and glycolysis were examined by CCK-8, flow cytometry, glucose uptake, lactate production and ECAR and OCR analysis, respectively. The CD8+ T cell…

N-Acetylornithine Depletion in Bone Marrow Biopsy: A Novel Microenvironment-Specific Hallmark for Multiple Myeloma Diagnosis.

INTRODUCTION: The bone marrow microenvironment plays crucial roles in the pathogenesis of multiple myeloma. Previous studies have shown that there are differences in the metabolomics of bone marrow suspension and plasma, but there is rare research on bone marrow biopsy tissue. This study aims to establish a new metabolomics approach to analyze bone marrow biopsy tissues and explore its diagnostic value. METHODS: We collected bone marrow biopsy tissues from 19 newly-diagnosed multiple myeloma(MM), 29 monoclonal gammaglobulinemia of undetermined significance(MGUS) and 30 lymphoma without bone m…

tRNA-derived fragment tRF-17-8SPOL52 induces resistance to bortezomib in multiple myeloma via autophagy activation.

Drug resistance limits the long-term survival of patients with multiple myeloma. The role of tRNA-derived fragments (tsRNAs) in bortezomib resistance in myeloma remains unknown. In this study, the most significantly upregulated tsRNA in relapsed/refractory myeloma was screened. RNA interference was used to explore the function of this tsRNA. The mechanism of the tsRNA-mediated resistance was explored by Ago-RIP-sequencing, dual-luciferase reporter assay, and transmission electron microscopy. tRF-17-8SPOL52 was identified as the most highly expressed tsRNA in relapsed/refractory myeloma. tRF-17…

Dynamic multimodal survival prediction in multiple myeloma integrating gene expression, longitudinal laboratory measurements, and treatment history.

Prognostic stratification in multiple myeloma (MM) relies on staging systems fixed at diagnosis, discarding temporal information accumulated during treatment. We developed a dynamic multimodal framework that predicts residual overall survival from observation windows of 1-18 months post-diagnosis. The model integrates DeepInsight-transformed gene expression, longitudinal trajectories of 10 laboratory analytes, and treatment history through missingness-aware gated fusion. On the Multiple Myeloma Research Foundation (MMRF) cohort from the Relating Clinical Outcomes in Multiple Myeloma to Persona…